Beta Drugs Ltd

BETA

Watchlist

AI Mode

‌

Market Cap

₹ 1,621 Cr

P/E

35.39

‌

‌
‌

‌

‌
‌

Investment Checklist

How to read checklist?

Performance

MARKET LEADER

Valuation

REASONABLE

Growth

STABLE

Profitability

HIGH MARGIN

Technicals

Bearish

Risk

MODERATE RISK

Investment Checklist

‌

‌
‌

‌

‌
‌

‌

‌
‌

‌

‌
‌

‌

‌
‌

‌

‌
‌

‌

Price

PE Ratio

Price

‌

Overview

Detailed Summary

Beta Drugs Limited is primarily engaged in manufacturing and marketing oncology drug products, catering to both domestic and international markets.

The company experienced a 13% revenue growth year-over-year, with notable expansions into 46+ countries, showcasing its extensive global reach and market acceptance.

Beta Drugs Limited acquired an oncology intermediate facility to enhance backward integration, reducing dependency on imports and improving margins.

Its entry into the cosmeceutical market through an exclusive agreement with Promoitalia marks a strategic diversification, enhancing their product offerings in high-end derma fillers.

The company is positioned for growth, focusing on developing in-house API capabilities and expanding its CDMO business, reflecting strategic investments in R&D and production capacities.

Sector

Pharmaceuticals

Industry

Pharmaceuticals - Indian - Bulk Drugs

Market Cap

1,621 Cr

Volatility

Moderate Risk

P/E Ratio

35.4

Industry P/E

59.2

PEG Ratio

13.1

P/B Ratio

8.2

52W High

2,050.43

52W Low

1,429.52

Sales CAGR

22.54%

20.82%

27.51%

10Y

—

Profit CAGR

16.41%

2.70%

16.80%

10Y

—

ROE

TTM

18.96%

16.46%

16.05%

10Y

16.89%

ROCE

TTM

18.07%

16.96%

17.77%

10Y

18.43%

Technicals

‌

Forecasts

Peers

Symbol	Price	Market Cap	P/E	P/B	Div Yield (%)	ROE (%)	ROCE (%)	ROA (%)
BETA	1605.50	1,621 Cr	35.39	8.22	0.00	18.96	18.07	0.00
FERMENTA	351.15	1,033 Cr	9.23	2.64	0.71	28.67	27.38	17.02
NGLFINE	1343.30	830 Cr	40.13	2.77	0.13	6.89	8.00	4.27
ANUHPHR	78.62	780 Cr	20.17	2.39	0.96	11.84	15.90	7.61
EVERESTO	470.00	458 Cr	69.23	6.31	0.00	9.12	9.87	2.79
INFINIUM	228.60	356 Cr	35.44	3.25	0.00	8.14	13.29	5.02
GENNEX	12.94	314 Cr	18.75	1.47	0.00	7.77	8.53	5.23

Financial Statements

AI Powered Summary

Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.

AI Mode

Consolidated Half Yearly Results (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2021	Sep 2021	Mar 2022	Sep 2022	Mar 2023	Sep 2023	Mar 2024	Sep 2024	Mar 2025	Sep 2025
Sales	65	88	96	112	115	141	154	180	182	204
Expenses	51	68	73	86	88	108	127	142	146	163
Interest	1.22	0.93	0.97	1.14	1.27	1.37	1.45	1.83	5.16	6.93
Operating Profit	14	20	23	27	26	33	27	39	36	41
OPM %	21.73	22.76	23.66	23.85	22.94	23.26	17.57	21.52	19.66	20.14
Other Income	0.24	0.45	0.30	0.33	0.43	0.54	0.82	1.51	0.36	5.98
Depreciation	3.68	3.31	3.95	4.83	5.58	5.44	4.34	5.71	6.80	7.97
Profit Before Tax	9.41	16	18	21	20	27	22	33	24	32
Tax %	30.50	27.74	27.49	25.19	25.18	25.24	25.30	25.44	25.67	25.46
Net Profit	6.54	12	13	16	15	20	17	24	18	24
EPS in Rs	—	—	—	—	—	—	—	—	—	—

Consolidated Profit Loss (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Sales	51	66	91	116	184	227	296	362
Expenses	41	54	73	91	141	174	236	288
Operating Profit	9.46	12	18	25	43	53	60	75
OPM %	18.70	17.91	19.72	21.31	23.23	23.39	20.29	20.59
Other Income	0.24	0.37	0.41	0.50	0.76	0.75	1.36	1.87
Interest	1.01	1.43	2.59	2.42	1.90	2.41	2.82	6.99
Depreciation	1.85	2.84	3.76	6.87	7.25	10	9.78	13
Profit Before Tax	6.84	7.91	12	16	34	41	49	57
Tax %	1.05	-1.69	21.36	26.50	27.62	25.18	25.26	25.54
Net Profit	6.76	8.04	9.42	12	25	31	36	42
EPS in Rs	—	—	—	—	—	—	—	—
Dividend Payout %	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00

Consolidated Balance Sheet (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Equity Capital	8.65	8.65	9.61	9.61	9.61	9.61	9.61	10
Reserves	24	32	47	59	83	113	148	187
Borrowings	6.16	18	20	15	17	16	11	133
Other Liabilities	11	24	30	34	49	59	86	106
Total Liabilities	50	83	107	118	158	198	254	436
Fixed Assets	13	18	44	40	55	63	65	89
CWIP	1.35	15	0.08	2.81	0.00	0.00	0.00	0.00
Investments	0.00	0.35	0.35	0.78	0.78	0.78	0.00	0.00
Other Assets	35	50	63	74	102	135	190	347
Total Assets	50	83	107	118	158	198	254	436

Consolidated Cash Flows (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operating Activity	17	0.11	8.41	19	30	23	31	36
Cash from Investing Activity	-11	-21	-15	-5.85	-22	-19	-14	-36
Cash from Financing Activity	5.45	12	8.73	-7.71	-0.97	-2.47	-7.49	118
Net Cash Flow	12	-8.61	2.09	5.04	6.90	1.84	9.47	118

Shareholdings

Shareholding History

Quarterly

Yearly

Quarterly

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Nov 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Nov 2025
Promoters	66.73%	66.73%	66.73%	66.73%	66.73%	66.73%	66.73%	66.73%	66.73%	66.73%	66.73%	66.73%
FIIs	0.29%	0.32%	0.32%	0.32%	0.90%	1.16%	1.16%	1.15%	0.90%	0.90%	0.91%	0.87%
DIIs	0.04%	0.02%	0.02%	0.06%	0.12%	0.16%	0.17%	0.17%	0.17%	0.26%	0.29%	0.32%
Public	32.94%	32.93%	32.92%	32.88%	32.25%	31.95%	31.94%	31.95%	32.20%	32.11%	32.07%	32.08%
Total Shareholders	1,451	1,722	1,928	2,116	2,323	2,567	2,793	2,882	3,045	3,139	3,184	3,003

Market Transactions

Date	Party	Category	Type	Avg Price (₹)	Total Value (₹)	Quantity	Percent Traded
Nov 13, 2025	Airavat capital trust ii	Bulk	Buy	1,686.00	26.29 Cr	1,55,925	1.54
Nov 13, 2025	Neeraj batra	Bulk	Sell	1,686.00	31.21 Cr	1,85,115	1.83

Projection

Actions

Action Type

‌
‌

Announcements

Last 7 days

Newest

Sentiment

Analyst/Investor Meet

4 days ago

Beta Drugs Limited Investor Meeting Scheduled

Beta Drugs Limited has announced a meeting with analysts and institutional investors on December 18, 2025, in Mumbai.

Documents

Presentations

Concalls

Reports

Presentations

Investor Presentation

Q2 FY26

Investor Presentation

Q2 FY25

Investor Presentation

Q4 FY24

Investor Presentation

Q2 FY24

Investor Presentation

Q4 FY23

Investor Presentation

Q2 FY23

Investor Presentation

Q4 FY22

Investor Presentation

Q2 FY22

Showing 1 - 8 of 9

AI Mode

Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.

AI Mode

Peers

Symbol	Price	Market Cap	P/E	P/B	Div Yield (%)	ROE (%)	ROCE (%)	ROA (%)
BETA	1605.50	1,621 Cr	35.39	8.22	0.00	18.96	18.07	0.00
FERMENTA	351.15	1,033 Cr	9.23	2.64	0.71	28.67	27.38	17.02
NGLFINE	1343.30	830 Cr	40.13	2.77	0.13	6.89	8.00	4.27
ANUHPHR	78.62	780 Cr	20.17	2.39	0.96	11.84	15.90	7.61
EVERESTO	470.00	458 Cr	69.23	6.31	0.00	9.12	9.87	2.79
INFINIUM	228.60	356 Cr	35.44	3.25	0.00	8.14	13.29	5.02
GENNEX	12.94	314 Cr	18.75	1.47	0.00	7.77	8.53	5.23

Financial Statements

AI Powered Summary

Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.

AI Mode

Consolidated Half Yearly Results (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2021	Sep 2021	Mar 2022	Sep 2022	Mar 2023	Sep 2023	Mar 2024	Sep 2024	Mar 2025	Sep 2025
Sales	65	88	96	112	115	141	154	180	182	204
Expenses	51	68	73	86	88	108	127	142	146	163
Interest	1.22	0.93	0.97	1.14	1.27	1.37	1.45	1.83	5.16	6.93
Operating Profit	14	20	23	27	26	33	27	39	36	41
OPM %	21.73	22.76	23.66	23.85	22.94	23.26	17.57	21.52	19.66	20.14
Other Income	0.24	0.45	0.30	0.33	0.43	0.54	0.82	1.51	0.36	5.98
Depreciation	3.68	3.31	3.95	4.83	5.58	5.44	4.34	5.71	6.80	7.97
Profit Before Tax	9.41	16	18	21	20	27	22	33	24	32
Tax %	30.50	27.74	27.49	25.19	25.18	25.24	25.30	25.44	25.67	25.46
Net Profit	6.54	12	13	16	15	20	17	24	18	24
EPS in Rs	—	—	—	—	—	—	—	—	—	—

Consolidated Profit Loss (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Sales	51	66	91	116	184	227	296	362
Expenses	41	54	73	91	141	174	236	288
Operating Profit	9.46	12	18	25	43	53	60	75
OPM %	18.70	17.91	19.72	21.31	23.23	23.39	20.29	20.59
Other Income	0.24	0.37	0.41	0.50	0.76	0.75	1.36	1.87
Interest	1.01	1.43	2.59	2.42	1.90	2.41	2.82	6.99
Depreciation	1.85	2.84	3.76	6.87	7.25	10	9.78	13
Profit Before Tax	6.84	7.91	12	16	34	41	49	57
Tax %	1.05	-1.69	21.36	26.50	27.62	25.18	25.26	25.54
Net Profit	6.76	8.04	9.42	12	25	31	36	42
EPS in Rs	—	—	—	—	—	—	—	—
Dividend Payout %	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00

Consolidated Balance Sheet (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Equity Capital	8.65	8.65	9.61	9.61	9.61	9.61	9.61	10
Reserves	24	32	47	59	83	113	148	187
Borrowings	6.16	18	20	15	17	16	11	133
Other Liabilities	11	24	30	34	49	59	86	106
Total Liabilities	50	83	107	118	158	198	254	436
Fixed Assets	13	18	44	40	55	63	65	89
CWIP	1.35	15	0.08	2.81	0.00	0.00	0.00	0.00
Investments	0.00	0.35	0.35	0.78	0.78	0.78	0.00	0.00
Other Assets	35	50	63	74	102	135	190	347
Total Assets	50	83	107	118	158	198	254	436

Consolidated Cash Flows (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operating Activity	17	0.11	8.41	19	30	23	31	36
Cash from Investing Activity	-11	-21	-15	-5.85	-22	-19	-14	-36
Cash from Financing Activity	5.45	12	8.73	-7.71	-0.97	-2.47	-7.49	118
Net Cash Flow	12	-8.61	2.09	5.04	6.90	1.84	9.47	118

Oscillators

BearishNeutralBullish

Neutral

Bearish

Neutral

Bullish

Overall

BearishNeutralBullish

Bearish

Neutral

Bullish

Moving Averages

BearishNeutralBullish

Bearish

Neutral

Bullish

Overall

BearishNeutralBullish

Bearish

Neutral

Bullish

Overview

Detailed Summary

Beta Drugs Limited is primarily engaged in manufacturing and marketing oncology drug products, catering to both domestic and international markets.

The company experienced a 13% revenue growth year-over-year, with notable expansions into 46+ countries, showcasing its extensive global reach and market acceptance.

Beta Drugs Limited acquired an oncology intermediate facility to enhance backward integration, reducing dependency on imports and improving margins.

Its entry into the cosmeceutical market through an exclusive agreement with Promoitalia marks a strategic diversification, enhancing their product offerings in high-end derma fillers.

The company is positioned for growth, focusing on developing in-house API capabilities and expanding its CDMO business, reflecting strategic investments in R&D and production capacities.

Sector

Pharmaceuticals

Industry

Pharmaceuticals - Indian - Bulk Drugs

Market Cap

1,621 Cr

Volatility

Moderate Risk

P/E Ratio

35.4

Industry P/E

59.2

PEG Ratio

13.1

P/B Ratio

8.2

52W High

2,050.43

52W Low

1,429.52

Sales CAGR

22.54%

20.82%

27.51%

10Y

—

Profit CAGR

16.41%

2.70%

16.80%

10Y

—

ROE

TTM

18.96%

16.46%

16.05%

10Y

16.89%

ROCE

TTM

18.07%

16.96%

17.77%

10Y

18.43%

Beta

Beta Drugs Ltd

BETA

AI Mode

Investment Checklist

Investment Checklist

Overview

Sector

Industry

Market Cap

Volatility

P/E Ratio

Industry P/E

PEG Ratio

P/B Ratio

52W High

52W Low

Technicals

Forecasts

Peers

Price Chart Comparison

Financial Statements

AI Powered Summary

AI Mode

Consolidated Half Yearly Results (in ₹ Crores)

Consolidated Profit Loss (in ₹ Crores)

Consolidated Balance Sheet (in ₹ Crores)

Consolidated Cash Flows (in ₹ Crores)

Shareholdings

Shareholding History

Market Transactions

Projection

Actions

Announcements

Documents

AI Mode

AI Mode

Technicals

Peers

Price Chart Comparison

Shareholdings

Shareholding History

Market Transactions

Financial Statements

AI Powered Summary

AI Mode

Consolidated Half Yearly Results (in ₹ Crores)

Consolidated Profit Loss (in ₹ Crores)

Consolidated Balance Sheet (in ₹ Crores)

Consolidated Cash Flows (in ₹ Crores)

Projection

Oscillators

Neutral

Overall

Bearish

Moving Averages

Bearish

Overall

Bearish

Beta Drugs Ltd

BETA

AI Mode

Forecasts

Announcements

Overview

Sector

Industry

Market Cap

Volatility

P/E Ratio

Industry P/E

PEG Ratio

P/B Ratio

52W High

52W Low

Investment Checklist